NASDAQ: CNTXContext Therapeutics Inc Stock
$1.41+0.02 (+1.44%)
Updated Apr 18, 2024
CNTX Price
$1.41
Fair Value Price
$0.91
Market Cap
$22.51M
52 Week Low
$0.47
52 Week High
$1.69
P/E
-0.94x
P/B
1.9x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$23.96M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.35
Operating Cash Flow
-$21M
Beta
0.9
Next Earnings
May 8, 2024
Ex-Dividend
N/A
Next Dividend
N/A
CNTX Overview
Context Therapeutics Inc. is a clinical-stage biopharmaceutical company developing cancer treatments for women. Candidates include ONA-XR (onapristone extended release) to treat female hormone-dependent cancers, and CLDN6xCD3 bsAb, intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6 (Claudin 6). The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics was incorporated in 2015 and is headquartered in Philadelphia, PA.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CNTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CNTX ($1.41) is overvalued by 55.8% relative to our estimate of its Fair Value price of $0.91 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
CNTX ($1.41) is not significantly undervalued (55.8%) relative to our estimate of its Fair Value price of $0.91 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CNTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CNTX due diligence checks available for Premium users.
Be the first to know about important CNTX news, forecast changes, insider trades & much more!
CNTX News
Valuation
CNTX fair value
Fair Value of CNTX stock based on Discounted Cash Flow (DCF)
Price
$1.41
Fair Value
$0.91
Overvalued by
55.80%
CNTX ($1.41) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CNTX ($1.41) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CNTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CNTX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.94x
Industry
15.68x
Market
41.33x
CNTX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.9x
Industry
5.76x
CNTX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CNTX's financial health
Profit margin
Revenue
$0.0
Net Income
-$6.8M
Profit Margin
0%
CNTX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$16.1M
Liabilities
$4.2M
Debt to equity
0.35
CNTX's short-term assets ($16.05M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CNTX's short-term assets ($16.05M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CNTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$7.2M
Investing
$0.0
Financing
$0.0
CNTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CNTX vs Biotech Stocks
Context Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.